Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

NCT01647906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2019-11-25

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.

Conditions

  • Fecal Incontinence

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2018-09-15
Completion
2018-09-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647906 on ClinicalTrials.gov